Myriad Genetics is exploding higher following the announcement that the company has entered into a definitive agreement to sell its prenatal health testing business to Labcorp for $210 million. This strategic divestiture, which was disclosed in the early hours of October 20, served as the primary catalyst for the stock's significant upward momentum. The move builds upon earlier pre-market activity where the shares initially surged 21.4% in response to the news.